Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Autolus Therapeutics stock
Own Autolus Therapeutics stock in just a few minutes.
Autolus Therapeutics plc is a biotechnology business based in the US. Autolus Therapeutics shares (AUTL) are listed on the NASDAQ and all prices are listed in US Dollars. Autolus Therapeutics employs 376 staff and has a trailing 12-month revenue of around USD$1.1 million.
How to buy shares in Autolus Therapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Autolus Therapeutics. Find the stock by name or ticker symbol: AUTL. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Autolus Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Autolus Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Autolus Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Autolus Therapeutics share price
Use our graph to track the performance of AUTL stocks over time.Autolus Therapeutics shares at a glance
Information last updated 2021-03-18.
| 52-week range | USD$4 - USD$17.19 |
|---|---|
| 50-day moving average | USD$7.0552 |
| 200-day moving average | USD$9.9381 |
| Wall St. target price | USD$15.78 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-1.4 |
Buy Autolus Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Autolus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Autolus Therapeutics financials
| Revenue TTM | USD$1.1 million |
|---|---|
| Gross profit TTM | USD$-133,173,000 |
| Return on assets TTM | -22.28% |
| Return on equity TTM | -29.62% |
| Profit margin | 0% |
| Book value | $5.91 |
| Market capitalisation | USD$486.5 million |
TTM: trailing 12 months
Shorting Autolus Therapeutics shares
There are currently 3.5 million Autolus Therapeutics shares held short by investors – that's known as Autolus Therapeutics's "short interest". This figure is 105.3% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Autolus Therapeutics shares can be evaluated.
Autolus Therapeutics's "short interest ratio" (SIR)
Autolus Therapeutics's "short interest ratio" (SIR) is the quantity of Autolus Therapeutics shares currently shorted divided by the average quantity of Autolus Therapeutics shares traded daily (recently around 1.3 million). Autolus Therapeutics's SIR currently stands at 2.67. In other words for every 100,000 Autolus Therapeutics shares traded daily on the market, roughly 2670 shares are currently held short.
However Autolus Therapeutics's short interest can also be evaluated against the total number of Autolus Therapeutics shares, or, against the total number of tradable Autolus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Autolus Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Autolus Therapeutics shares in existence, roughly 50 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Autolus Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Autolus Therapeutics.
Find out more about how you can short Autolus Therapeutics stock.
Autolus Therapeutics share dividends
We're not expecting Autolus Therapeutics to pay a dividend over the next 12 months.
Autolus Therapeutics share price volatility
Over the last 12 months, Autolus Therapeutics's shares have ranged in value from as little as $4 up to $17.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Autolus Therapeutics's is 1.7544. This would suggest that Autolus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Autolus Therapeutics overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. .
Frequently asked questions
More guides on Finder
-
T. Rowe Price review
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
-
How to buy ZTO Express Cayman stock
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
-
How to buy Zomedica stock
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
-
How to buy ZoomInfo Technologies stock
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
-
How to buy ZK International Group CoLtd stock
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
-
How to buy Zions Bancorporation National Association stock
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
-
How to buy Zentalis Pharmaceuticals stock
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
-
How to buy Yunhong International stock
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
-
How to buy Zealand Pharma A/S stock
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
-
How to buy Yunhong CTI stock
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
Ask an Expert